PharmaShots Weekly Snapshot (February 18 - 22, 2019)
Published: 22 Feb,2019 | Tags: Mallinckrodt, Reports, Results, Therakos Photopheresis, Therapy, P-III study, Steroid-Refractory Acute Graft-Versus-Host Disease, aGvHD
Published: 22 Feb,2019 | Tags: Eurofarma, Signs, Exclusive, Development, Commercialization, Agreement, NLS-1 Pharma, ADHD, Nalazol, America
Published: 22 Feb,2019 | Tags: Janssen, Signs, Research, Development, Agreement, Morphic, Development, Human Integrins Therapeutics
?Published: 22 Feb,2019 | Tags: Amgen, Reports, Initiation, Second, P-III, METEORIC-HF Study, Omecamtiv Mecarbil, Patients, Heart Failure, PBO
5. AbbVie & Eisais Humira (adalimumab) Receives Approval for Hidradenitis Suppurativa in Japan
Published: 22 Feb,2019 | Tags: AbbVie, Eisai, Humira, adalimumab, Receives, Approval, Hidradenitis Suppurativa, Japan
6. Merck to Acquire Immune Design for its Technologies for $300M
Published: 21 Feb,2019 | Tags: Merck, Acquire, Immune Design, Technologies, $300M, GLAAS, ZVex
Published: 21 Feb,2019 | Tags: AbbVie, Humira, adalimumab, Receives, Health Canada, Approval, Chronic Non-Infectious Anterior Uveitis, Pediatric, Patients
8. Novo Nordisk Signs Non -Exclusive Agreement with Abbott for its FreeStyle Libre Mobile App
Published: 21 Feb,2019 | Tags: Novo Nordisk, Signs, Non -Exclusive, Agreement, Abbott, FreeStyle Libre Mobile App
Published: 21 Feb,2019 | Tags: Mustang Bio, Signs, Exclusives, Worldwide, Collaboration, Nationwide Childrens Hospital, Glioblastoma Multiforme, MB-101, C134
Published: 21 Feb,2019 | Tags: Merck, Reports, Results, Keytruda, pembrolizumab, P-III, KEYNOTE-240, 1L, Advanced Hepatocellular Carcinoma, HCC
11. Pfizer and Lilly Report Result of Tanezumab in P-III A4091059 Study for Chronic Low Back Pain (CLBP)
Published: 20 Feb,2019 | Tags: Pfizer, Lilly, Report, Results, Tanezumab, P-III, A4091059, Study, Chronic Low Back Pain,
12. Bausch + Lomb Licenses US Commercial Rights for Eton Pharmaceuticals EM-100 to Treat Ocular Itching
Published: 20 Feb,2019 | Tags: Bausch + Lomb, Licenses, US, Commercial Rights, Eton Pharmaceuticals, EM-100, Ocular Itching, Subsidary, Bausch Health
Published: 20 Feb,2019 | Tags: Alkermes, Signs, Research, Agreement, Clovis Oncology, Evaluate, ALKS 4230, Combination, Rucaparib, Lucitanib
Published: 20 Feb,2019 | Tags: Novo Nordisk, Esperoct, turoctocog alfa pegol, N8-GP, Receives, FDA, Approval, Adults, Children, Haemophilia A
Published: 20 Feb,2019 | Tags: Merck, Keytruda, pembrolizumab, Receives, FDA, Approval, Adjuvant, Treatment, Patients, Melanoma, Involvement, Lymph Node
Published: 19 Feb,2019 | Tags: AVEO Oncology, Reports, Results, FOTIVDA, tivozanib, P-III, TIVO-3, Study, Refractory, Advanced, Metastatic, Renal Cell Carcinoma, RCC
Published: 19 Feb,2019 | Tags: Chipscreen Biosciences, Collaborates, Evaluate, Chidamide, Innovent Biologics, Sintilimab, Anti-VEGF, IBI305, China
Published: 19 Feb,2019 | Tags: Roche, Polatuzumab Vedotin, Combination, Therapy, Entrectinib, Receives, FDA, Priority Review
19. Japan Ministry of Health Approves Use of Induced Pluripotent Stem Cells (iPSCs) for Spinal Injuries
Published: 19 Feb,2019 | Tags: Japan Ministry of Health, Approves, Induced Pluripotent Stem Cells, iPSCs, Spinal Injuries, H12019, Keio University
Published: 19 Feb,2019 | Tags: Pfizer, Reports, Results, Bavencio, avelumab, Inlyta, axitinib, P-III, JAVELIN Renal 101 trial, 1L, Advanced, Renal, Cell Carcinoma, RCC
Published: 18 Feb,2019 | Tags: Finch Therapeutics, CP101, Receives, FDA, Breakthrough Therapy Designation, BT, Recurrent Clostridium difficile, C. difficile, Infection
22. Medtronic to Recall its Dual Chamber Implantable Pulse Generators (IPGs) in the US
Published: 18 Feb,2019 | Tags: Medtronic, Recall, Dual Chamber Implantable Pulse Generators, IPGs, the US, Class I recall, the US FDA
Published: 18 Feb,2019 | Tags Bayer, Exercises, Exclusive, WorldWide, Option, License, Vitrakvi, larotrectinib, BAY 2731954, LOXO-195, LOXO Oncology
Published: 18 Feb,2019 | Tags Merck, Reports, Results, Keytruda, pembrolizumab, Inlyta, axitinib, P-III, KEYNOTE-426 Study, Patients, 1L, Advanced Renal Cell Carcinoma, RCC